

EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY 55th Annual ESPE Meeting 2016 10-12 September 2016 Paris



171

SEVERE HYPERTRIGLYCERIDEMIA IN PEDIATRIC ONCOLOGY PATIENT.

Portillo Nancy^{1,3}, Grau Gema^{1,3}, Lopez Ricardo^{2,3}, Echebarria Aizpea^{2,3}, Astlgarraga Itziar^{2,3} and Rica Itxaso ^{1,3}.

Paediatric Endocrinology.¹ Paediatric Oncology². Cruces University Hospital. BioCruces. ³

Background:

Severe Hypertriglyceridemia (HTG) defined as triglycerides (TG) in blood plasma higher than 1000 mg /dl is a rare condition in childhood. Its causes are classified as primary and secondary and among these last they include pharmacological causes. Steroids associated with some chemotherapy drugs, particularly asparaginase (Asp), are a combination with special risk.

Objectives

Describe the evolution of lipids profile in acute lymphoblastic leukemia (ALL) patients, treated with steroids associated with Asparaginase (Asp),

Methods

Retrospective descriptive study of cases of severe HTG in patients with ALL treated in a tertiary hospital in 2010-2015. We have studied the prevalence of this disorder and its characteristics. Patients were treated on the LLA SHOP-2005 or LLA SHEOP-PETHEMA 2013 with an average of 23 dose of intramuscular Steroids-Asp (prednisone 60 mg / m2 / day, or dexamethasone 8 mg / m2 / day) patient and distributed in 3 blocks of treatment .

RESULTS

- 45 patients were diagnosed with ALL (mean age 5 years old, male / female: 1.5 / 1).
- Protocols: ALL SHOP-2005 (49%) and ALL SHEOP-PETHEMA 2013 (51%);
- 102 estimated blocks with Steroids-Asp

3,5

D

3,799

- It was found **severe HTG in 4 patients** with steroid-Asp (prevalence of 4%).
- The mean age was 7 years. Three were high-risk ALL.
- No relationship with other medications received was found.
- The **evolution** of HTG was adequate regardless of the therapeutic approach.

522

	: - + · · - + ! - · ·		
admin	istration.		

• No acute clinical **complications**.

771

Patient	Age (years)	TG (mg/dL)	Treatment	TG 3 days (mg/dl)	TG 1 week (mg/dl)	TG 3 months (mg/dl)
A	14,5	>7,000	Bezafibrate (6 mg/kg/día)	2,836	244	NA
B	7,7	6,280	Bezafibrate (10 mg/kg/día)	323	123	91
С	5,9	2,200	None	252	340	314

None

CONCLUSIONS

The Asp and steroids can produce a transient severe HTG. Its management is based on dietary modifications +/lipid lowering agents, and close monitoring without altering chemotherapy. No serious acute complications observed in any case.

